When caring for a patient receiving autolytic debridement
therapy, the nurse
a) advises the patient about the foul odor that will occur during
therapy.
During autolytic debridement therapy a foul odor will be produced by
the breakdown of cellular debris. This odor does not indicate that the
wound is infected.
b) ensures that the dressing is kept dry at all times.
During autolytic debridement therapy the wound is kept moist.
c) ensures that the wound is kept open to the air for at least six hours
per day.
During autolytic debridement therapy the wound is covered with an
occlusive dressing.
d) Uses an enzymatic debriding agent such as Pancrease.
Commercially available enzymatic debriding agents include Accuzyme,
Clooagenase, Granulex, and Zymase.
therapy, the nurse
a) advises the patient about the foul odor that will occur during
therapy.
During autolytic debridement therapy a foul odor will be produced by
the breakdown of cellular debris. This odor does not indicate that the
wound is infected.
b) ensures that the dressing is kept dry at all times.
During autolytic debridement therapy the wound is kept moist.
c) ensures that the wound is kept open to the air for at least six hours
per day.
During autolytic debridement therapy the wound is covered with an
occlusive dressing.
d) Uses an enzymatic debriding agent such as Pancrease.
Commercially available enzymatic debriding agents include Accuzyme,
Clooagenase, Granulex, and Zymase.